Company Comparison
Ginkgo Bioworks vs 23andMe
Side-by-side comparison of two portfolio companies — sector, funding stage, investors, valuation, and more.
| Metric | Ginkgo Bioworks | 23andMe |
|---|---|---|
| Sector | Biotech | Biotech |
| Headquarters | — | South San Francisco, California |
| Founded | 2008 | 2006 |
| Status | Active | Active |
| Last Funding Stage | — | — |
| Total Funding | $290M | — |
| Valuation | $4.2B | — |
What They Build
Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly.
23andMe
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California.
Key Investors
Ginkgo Bioworks
Sector Overlap
Both Ginkgo Bioworks and 23andMe operate in Biotech.
Browse all Biotech companies →Websites
The operating system for private capital.
Archstone runs the back office for venture, PE, real estate, and credit funds — LP reporting, capital calls, portfolio tracking, and fund accounting, in one platform. Now in alpha.
Now in alpha with select funds. 14-day trial available.